Developing drugs for cognitive impairment in schizophrenia.

There are strong data suggesting that improvement in the cognitive impairment associated with schizophrenia will contribute to enhanced functional outcomes for patients with this illness. Measurement and Treatment Research to Improve Cognition in Schizophrenia was established to provide a pathway for developing and registering potential cognitive-enhancing agents for this condition by addressing issues related to the content of the cognitive assessment battery and the clinical design features to be used in registration studies. This article examines key challenges related to the actual clinical development of cognitive-enhancing agents. These challenges include improving the probability of technical success and attrition rates of candidate molecules, establishing better animal models of human cognition, and developing biomarkers to decrease development costs and increase the speed of the clinical discovery process. Biomarkers are important for molecular target validation, dose selection, surrogate end points, and population segmentation. Examples of approaches for the development of agents for cognitive impairment associated with schizophrenia are discussed. It is concluded that close collaboration among academia, the National Institutes of Health, regulatory bodies, and industry will be important to advance the goal of developing drugs for this important condition.

[1]  D. Braff,et al.  Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. , 2005, Archives of general psychiatry.

[2]  J. Callicott,et al.  Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. , 2004, The American journal of psychiatry.

[3]  L. Fañanás,et al.  New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. , 2004, The American journal of psychiatry.

[4]  R. Strausberg,et al.  Oncogenomics and the development of new cancer therapies , 2004, Nature.

[5]  Sridhar Ramaswamy,et al.  Translating cancer genomics into clinical oncology. , 2004, The New England journal of medicine.

[6]  R. Coppola,et al.  Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. , 2003, Archives of general psychiatry.

[7]  B. Druker.  Imatinib mesylate in the treatment of chronic myeloid leukaemia , 2003, Expert opinion on pharmacotherapy.

[8]  T. Patterson,et al.  Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community living situations of older patients with psychosis. , 2002, The American journal of psychiatry.

[9]  Richard Hargreaves,et al.  Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. , 2002, The Journal of clinical psychiatry.

[10]  J. Calabrese,et al.  Long-term treatment of bipolar disorder with lamotrigine. , 2002, The Journal of clinical psychiatry.

[11]  J. Lieberman,et al.  Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia , 2002, Biological Psychiatry.

[12]  T. Patterson,et al.  Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving , 2002, Schizophrenia Research.

[13]  B. Druker,et al.  STI571 (Gleevec) as a paradigm for cancer therapy. , 2002, Trends in molecular medicine.

[14]  Daniel R. Weinberger,et al.  Prefrontal neurons and the genetics of schizophrenia , 2001, Biological Psychiatry.

[15]  R. Straub,et al.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Philip D. Harvey,et al.  Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. , 2001, The American journal of psychiatry.

[17]  Jeremy M Crook,et al.  Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation , 2000, Biological Psychiatry.

[18]  Jane S. Paulsen,et al.  Generalized cognitive deficits in schizophrenia: a study of first-episode patients. , 1999, Archives of general psychiatry.

[19]  F. Bymaster,et al.  Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. , 1999, The Journal of pharmacology and experimental therapeutics.

[20]  R. Drake,et al.  A randomized clinical trial of supported employment for inner-city patients with severe mental disorders. , 1999, Archives of general psychiatry.

[21]  T. Barnes,et al.  Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics* , 1999, British Journal of Psychiatry.

[22]  B. Dean,et al.  The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. , 1999, Life sciences.

[23]  Humberto Temporini,et al.  Pharmacologic strategies for augmenting cognitive performance in schizophrenia , 1999, Biological Psychiatry.

[24]  F. Bymaster,et al.  Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane . , 1998, European journal of pharmacology.

[25]  W W Offen,et al.  Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. , 1997, Archives of neurology.

[26]  R. Weinshilboum,et al.  Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. , 1996, Pharmacogenetics.

[27]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[28]  B. Dean,et al.  The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. , 1996, Molecular psychiatry.

[29]  I. Ulmanen,et al.  Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. , 1995, Biochemistry.

[30]  R. Gur,et al.  Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. , 1994, Archives of general psychiatry.

[31]  D L Braff,et al.  The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. , 1991, Archives of general psychiatry.

[32]  D. Pickar,et al.  National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. , 1991, Archives of general psychiatry.

[33]  L. Thal,et al.  Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers. , 1989, The Journal of pharmacology and experimental therapeutics.

[34]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[35]  S. Snyder,et al.  Neurotransmitter receptors in frontal cortex of schizophrenics. , 1979, Archives of general psychiatry.

[36]  A. Cudennec,et al.  Deficits in passive-avoidance learning following atropine in the developing rat , 1977, Psychopharmacology.

[37]  Douglas W. Jones,et al.  In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. , 2003, The American journal of psychiatry.

[38]  D. Jeste,et al.  Stability and course of neuropsychological deficits in schizophrenia. , 2001, Archives of general psychiatry.

[39]  J. Lieberman,et al.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. , 1999, Schizophrenia bulletin.

[40]  R. Buchanan,et al.  Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. , 1994, The American journal of psychiatry.

[41]  M. Mishkin,et al.  The effects of physostigmine and scopolamine on recognition memory in monkeys. , 1986, Behavioral and neural biology.